Published in final edited form as:

Microvasc Res. 2020 November ; 132: 104042. doi:10.1016/j.mvr.2020.104042.

Three-dimensional induced pluripotent stem-cell models of human brain angiogenesis

Raleigh M. Linville^{1,2}, Diego Arevalo^{1,2}, Joanna C. Maressa^{1,3}, Nan Zhao¹, Peter C. Searson^{1,2,3,*}

¹Institute for Nanobiotechnology, Johns Hopkins University, Baltimore, MD

²Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD

³Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, MD

Abstract

During brain development, chemical cues released by developing neurons, cellular signaling with pericytes, and mechanical cues within the brain extracellular matrix (ECM) promote angiogenesis of brain microvascular endothelial cells (BMECs). Angiogenesis is also associated with diseases of the brain due to pathological chemical, cellular, and mechanical signaling. Existing *in vitro* and *in vivo* models of brain angiogenesis have key limitations. Here, we develop a high-throughput *in vitro* blood-brain barrier (BBB) bead assay of brain angiogenesis utilizing 150 μ m diameter beads coated with induced pluripotent stem-cell (iPSC)-derived human BMECs (dhBMECs). After

*corresponding author: Peter C. Searson, PhD, 100 Croft Hall, Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, searson@jhu.edu, 410 516 8774.

AUTHOR STATEMENT

Raleigh M. Linville: Conceptualization, Investigation, Formal analysis, Writing - Original Draft, Writing - Review & Editing

Diego Arevalo: Investigation, Writing - Review & Editing

Joanna C. Maressa: Investigation, Writing - Review & Editing

Nan Zhao: Investigation, Writing - Review & Editing

Peter C. Searson: Conceptualization, Writing - Review & Editing, Supervision

Author contributions

RML and DA designed, conducted, and analyzed bead assay experiments. RML, JM, and NZ designed, conducted, and analyzed microvessel experiments. RML and PCS wrote the manuscript. All authors read and approved the final manuscript.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflicts of interest

Not applicable.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

The raw and processed data from this study are available from the corresponding author.

Code availability

Not applicable.

Competing interests

The authors declare no conflict of interest.

embedding the beads within a 3D matrix, we introduce various chemical cues and extracellular matrix components to explore their effects on angiogenic behavior. Based on the results from the bead assay, we generate a multiscale model of the human cerebrovasculature within perfusable three-dimensional tissue-engineered blood-brain barrier microvessels. A sprouting phenotype is optimized in confluent monolayers of dhBMECs using chemical treatment with vascular endothelial growth factor (VEGF) and wnt ligands, and the inclusion of pro-angiogenic ECM components. As a proof-of-principle that the bead angiogenesis assay can be applied to study pathological angiogenesis, we show that oxidative stress can exert concentration-dependent effects on angiogenesis. Finally, we demonstrate the formation of a hierarchical microvascular model of the human blood-brain barrier displaying key structural hallmarks. We develop two *in vitro* models of brain angiogenesis: the BBB bead assay and the tissue-engineered BBB microvessel model. These platforms provide a tool kit for studies of physiological and pathological brain angiogenesis, with key advantages over existing two-dimensional models.

Graphical Abstract

Keywords

brain angiogenesis; induced pluripotent stem cells; brain microvascular endothelial cells; microvascular tissue engineering; blood-brain barrier; brain capillaries

1. Introduction

Brain angiogenesis is a multistage process by which new capillaries sprout from existing blood vessels. The culmination of brain angiogenesis during development results in a 600 km network of capillaries forming the blood-brain barrier (BBB) [1]. Brain microvascular endothelial cells (BMECs), which form the interface between the vascular system and the brain parenchyma, regulate transport into the brain via expression of tight junctions (TJs), efflux pumps, and nutrient transporters [2, 3]. The ability to study brain angiogenesis *in vitro* has been limited by a lack of 3D models and an appropriate source of brain microvascular endothelial cells. Consequently, previous studies have relied on two-dimensional assays such as the Matrigel tube assay and cord-forming assays, or utilize primary / immortalized cells, which display an incomplete BBB phenotype [4-6].

To enable imaging of angiogenesis in 3D, we have adapted the fibrin bead angiogenesis assay [7], forming a confluent monolayer of iPSC-derived brain microvascular endothelial cells (dhBMECs) on microbeads (BBB beads). The beads are then embedded in a collagen I

hydrogel, which mimics the native stiffness of brain parenchyma [8]. We then explore how changes in the chemical and extracellular matrix microenvironment influence angiogenesis. We report on the influence of pro-angiogenic cues including vascular endothelial growth factor (VEGF) [9], *wnt7a/b* [10], and basement membrane [11]. In addition, to mimic pathological angiogenesis in response to oxidative stress, we report on the dose-dependent effects of hydrogen peroxide.

dhBMECs have emerged as an attractive cell source for BBB models as: (1) species differences mean that animal models do not always recapitulate human disease [12, 13], (2) reliable and diverse protocols have been developed to differentiate BMECs [14-16], and (3) patient-specific and CRISPR gene-edited iPSCs are available for controlled studies on how genetic mutations impact cell phenotype [17-19]. Additionally, dhBMECs recapitulate key aspects of BBB phenotype including high transendothelial electrical resistance, restriction of paracellular permeability, and efflux activity [3] [20]. Primary and immortalized BMECs, which de-differentiate during *in vitro* culture [21], are often deficient in these characteristics and are not easily scalable for isogenic or patient-specific studies [22].

We also apply our results from the BBB bead angiogenesis assay to improve design of tissue-engineered hierarchical BBB models. Existing 3D models of brain angiogenesis based on selforganization approaches [23-25] fail to recapitulate the hierarchy of the human BBB, consisting of capillaries fed by an input arteriole and output venule. Engineering hierarchical microvascular models is limited by the spatial and temporal resolution of current techniques [25-28]. Our lab has demonstrated a hybrid approach relying on both templating and angiogenesis to form hierarchical microvascular networks using human umbilical vein endothelial cells (HUVECs) [29]. Here, after formation of microvessels resembling post-capillary venules (PCVs) by seeding dhBMECs into channels patterned within ECM [30], we apply optimized angiogenic factors to promote sprouting and anastomosis between adjacent microvessel to recapitulate a key aspect of human BBB function, low solute permeability. Our three-dimensional models provide a diverse toolbox for studies of brain angiogenesis.

2. Materials and methods

2.1. Cell culture

Brain microvascular endothelial cells (BMECs) were differentiated from hiPSCs similar to published protocols [16, 30]. The WTC iPSC line [31] with red fluorescent protein-tagged plasma membrane (Allen Cell Institute) was used to facilitate live-cell monitoring of angiogenesis. WTC iPSCs were plated at 10,000 cells cm⁻² on Matrigel-coated plates and grown for two days in mTESR1 (StemCell Technologies) to approximately 25% confluency, with 10 μ M ROCK inhibitor Y27632 (RI; ATCC) supplemented for the initial 24 hours. Subsequent six-day treatment with unconditioned media without bFGF (UM/F-); DMEM/F12 (Life Technologies) supplemented with 20% knockout serum replacement (Life Technologies), 1% non-essential amino acids (Life Technologies), 0.5% GlutaMAX (Life Technologies) and 0.836 μ M beta-mercaptoethanol (Life Technologies), and two-day treatment with RA media: human endothelial cell serum-free media (Life Technologies) supplemented with 1% human platelet poor derived serum (Sigma), 2 ng mL⁻¹ bFGF (R&D

Systems), and 10 μM all-trans retinoic acid (RA; Sigma) produces dhBMECs. Differentiations were conducted over a ten-passage window on six-well plates using media volumes of 1 mL and daily media switches. Transendothelial electrical resistance (TEER) measurements were used to confirm the quality of differentiations as previously reported [16]; the average TEER for WTC-RFP cells after 48 hours was $\sim 2,500 \Omega \text{ cm}^2$.

VeraVec HUVEC-TURBO-GFP cells (HUVECs; Angiocrine Bioscience) were used as a non-brain specific endothelial cell control. HUVECs were grown in “HUVEC media”: MCDB 131 (Caisson) supplemented with 10% fetal bovine serum (Sigma), 1% pen-strep-glut (Thermo Fisher), 1 $\mu\text{g mL}^{-1}$ hydrocortisone (Sigma), 10 $\mu\text{g mL}^{-1}$ heparin (Sigma), 25 $\mu\text{g mL}^{-1}$ endothelial cell growth supplement (Thermo Fisher), and 0.2 mM ascorbic acid 2-phosphate (Sigma). HUVECs were used until passage 7 and routinely passed using TryPLE Express (Life Technologies).

2.2. Forming endothelial monolayers on microbeads

Assay protocols were adapted from those developed for primary endothelial cells [7]. 150 μm diameter Cytodex™ 3 microcarrier beads (GE Healthcare) were prepared according to manufacturer recommendations. Beads were coated overnight with 50 $\mu\text{g mL}^{-1}$ human placental collagen IV (Sigma) and 25 $\mu\text{g mL}^{-1}$ fibronectin from human plasma (Sigma). dhBMECs were singularized using 30 minute StemPro accutase (ThermoFisher) treatment and incubated at a ratio of 1000:1 (dhBMECs:beads) for two hours under gentle agitation every 30 minutes. “Bead seeding media” was comprised of human endothelial cell serum-free media (Life Technologies) supplemented with 1% human platelet poor derived serum (Sigma), 1% Penicillin Streptomycin (Thermo Fisher), 2 ng mL^{-1} bFGF (R&D Systems), 10 μM all-trans retinoic acid (Sigma), and 10 μM ROCK inhibitor Y27632 (RI). Inclusion of RI was required to enable cell adhesion, as previously found for collagen-based biomaterials [32]. After two hours, non-adherent dhBMECs were removed and beads were cultured for 24 hours on a shaker at 100 rpm in bead seeding media. To form HUVEC coated beads, identical protocols were used with the following differences: (1) incubation with cells for only one hour, (2) use of HUVEC media without supplementation with RI.

2.3. Immunocytochemistry

After 24 hours on a shaker (day 1), beads were fixed and stained to assess protein expression. Beads were rinsed with room-temperature phosphate-buffered saline (PBS; ThermoFisher) and then collected using brief centrifugation (30 seconds at 0.3 g). Beads were fixed using ice-cold methanol for 15 minutes, blocked for 30 minutes in PBS with 10% normal goat serum (Cell Signaling Technology) and 0.3% Triton X-100 (Millipore Sigma), and then treated with primary antibodies diluted in blocking buffer overnight at 4 °C (see Supplementary Table S1 for details). After washing with PBS three times, cells were treated with 1:200 Alexa Flour-488 or Alexa Flour-647 secondary antibodies (Life Technologies) diluted in blocking buffer for 45 minutes at room temperature. To physically constrain beads for confocal imaging and to stain cell nuclei, beads were loaded onto eight-chambered borosilicate cover glass wells with Fluoromount-G with DAPI (Invitrogen). Confocal images were acquired at 40x magnification on a swept field confocal microscope system (Prairie Technologies) with illumination provided by an MLC 400 monolithic laser combiner

(Keysight Technologies). As a negative control, beads were not exposed to primary antibodies to determine signal due to non-specific secondary antibody binding. To conduct immunocytochemistry of microvessels, antibodies and buffers were perfused through microvessel lumens with identical incubation times.

2.4. Permeability assay

Beads were suspended in 200 μ M Lucifer yellow (CH dilithium salt; LY) (Sigma) to confirm restriction of paracellular transport. After three hours, confocal images were acquired at the bead midplane to determine accumulation of LY from the fluorescence within beads. Three conditions were tested: (1) blank beads without LY, (2) blank beads with LY, and (3) dhBMEC beads with LY. A circular region of interest (ROI) within beads was used to compare normalized fluorescence intensity across conditions.

2.5. Bead angiogenesis assay

On day 1 (24 hours after seeding dhBMECs), beads were suspended into hydrogels at ~ 100 beads mL^{-1} and gelled in a 250 μ L volume within eight-chambered borosilicate cover glass wells (Lab Tek). Hydrogels were comprised of 6 mg mL^{-1} neutralized rat tail type I collagen (Corning). After 30 minutes of gelation, cell culture media was added on top of hydrogel and replenished daily. Both cell culture media and ECM conditions were toggled to optimize angiogenic growth. Basal media consisted of human endothelial cell serum-free media (Life Technologies) supplemented with 1% human platelet poor derived serum (Sigma) and 1% Penicillin Streptomycin (Thermo Fisher). Basal media was further supplemented with 20 ng mL^{-1} bFGF (R&D Systems), 50 ng mL^{-1} recombinant human Wnt-7a (Wnt7a; Fisher Scientific), and 50 ng mL^{-1} recombinant human VEGF-165 (VEGF; Biolegend). In some experiments, hydrogels were supplemented with additional ECM components, including 1.5 mg mL^{-1} growth factor reduced Matrigel (Corning), 1.5 mg mL^{-1} fibrin, and 0.5 mg mL^{-1} fibronectin from human plasma. Fibrin composite hydrogels were formed by combining 2 U mL^{-1} thrombin from bovine plasma (Sigma) with 6 mg mL^{-1} neutralized rat tail type I collagen (Corning), before addition of 1.5 mg mL^{-1} fibrinogen from bovine plasma (Sigma). Across all experiments, media was replenished daily (250 μ L volume).

2.6. Imaging and analysis

Phase contrast and epifluorescence images (Texas Red filter) of beads were acquired on an inverted microscope (Nikon Eclipse TiE) at 10x magnification. For each experimental condition, ten images (technical replicates) of individual beads were collected at day 2, 4 and 6 after embedding in hydrogels. Beads whose endothelium grew along the glass-collagen interface were excluded from analysis. Angiogenic sprouts were defined as perpendicular protrusions from beads, with length greater than thickness. Three measures were calculated in ImageJ (NIH): (1) Angiogenic percentage (%), defined as the percentage of beads that display angiogenic sprouts, (2) sprout density (# bead $^{-1}$), and (3) maximum sprout length (μ m).

2.7. Modeling oxidative stress

Hydrogen peroxide (H_2O_2 ; Sigma) was prepared in water and then supplemented in media to final concentrations of 1 mM and 10 μM . Vehicle treatment consisted of 1% water. H_2O_2 was added after embedding beads in hydrogels and was included in daily media switches. All oxidative stress experiments were conducted in 6 mg mL^{-1} rat tail type I collagen and 1.5 mg mL^{-1} Matrigel, treated with basal media for 6 days.

2.8. Microvessel fabrication

Three-dimensional BBB microvessels were fabricated as previously reported [30]. Briefly, 1 cm (length) x 1.75 mm (width) x 1 mm (height) channels were cast in polydimethylsiloxane (PDMS; Dow Corning) using an aluminum mold. Neutralized 6 mg mL^{-1} rat tail type I collagen supplemented with 1.5 mg mL^{-1} Matrigel was gelled surrounding a template 150 μm diameter super-elastic nitinol wire (Malin Co.). After 30 minutes at 37 $^{\circ}\text{C}$, template wires were removed to leave behind a channel that was subsequently seeded with singularized dhBMECs. Microvessels were perfused under ~ 2 dyne cm^{-2} shear stress using fluid reservoirs as previously reported [8]. For the first 24 hours, “bead seeding medium” was perfused through channels to promote microvessel formation. Then, experimental media were perfused for 6 days.

2.9. Hierarchical model

A hierarchical microvascular model was fabricated based on a previously reported model using HUVECs [29]. Two template 150 μm diameter super-elastic nitinol wires were suspended with a separation distance (d) of 100 – 200 μm . Microvessels were perfused at 2 dyne cm^{-2} shear stress. All hierarchical models were generated in 6 mg mL^{-1} rat tail type I collagen and 1.5 mg mL^{-1} Matrigel, perfused with basal media + 20 ng mL^{-1} bFGF for 5 days. To assess barrier function, 2 μM 500 kDa dextran (Thermo Fisher) was perfused through microvessels for thirty minutes before, during, and after anastomosis. Phase contrast and fluorescence images were acquired every two minutes, as previously reported [8]. ImageJ was used to plot fluorescence intensity over time, where permeability is calculated as $(r/2)(1/I)(dI/dt)_0$, where r is the microvessel radius, I is the jump in total fluorescence intensity upon luminal filling, and $(dI/dt)_0$ is the rate of increase in total fluorescent intensity over one hour [30, 33].

2.10. Statistical Analysis

Statistical testing was performed using Prism ver. 8 (GraphPad). Measures are reported as mean $\pm$ standard error of the mean (SEM). A one-way analysis of variance (ANOVA) test was used for comparison of three or more groups. Reported p-values were multiplicity adjusted using a Tukey test. Differences were considered statistically significant for $p < 0.05$, with the following thresholds: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

3. Results

3.1. Fabrication of a three-dimensional model of brain angiogenesis

To assess the angiogenic potential of iPSC-derived brain microvascular endothelial cells (dhBMECs), we adapted the bead angiogenesis assay [7]. dhBMECs were differentiated from the WTC iPSC line with a fluorescently-tagged plasma membrane (Fig. 1a, b). Beads were coated with extracellular matrix (ECM) proteins collagen IV and fibronectin, and then incubated with dhBMECs for 2 hours to achieve a uniform coating (Fig. 1c, d). Beads were cultured for 24 hours to enable the formation of a confluent monolayer of dhBMECs (BBB beads). The beads were then embedded within extracellular matrix (ECM) to study chemical and physical cues that guide angiogenesis. An entire six-well plate of dhBMECs is sufficient for coating ~12,000 beads, demonstrating the scalability of our approach.

Beads coated with dhBMECs display expression of key BBB and endothelial markers, including claudin-5, occludin, glucose transporter 1 (GLUT1), p-glycoprotein (Pgp), and CD31 (Fig. 2a), as previously reported in 2D assays [14-16]. Protein expression of BBB markers was unique to dhBMECs, while the endothelial marker (CD31) was also expressed by human umbilical vein endothelial cells (HUVECs) (Supp. Fig. 1). Additionally, BBB beads express the critical angiogenic ligand receptors fibroblast growth factor receptor 2 (FGFR2), vascular endothelial growth factor receptor 2 (VEGFR2), and G protein-coupled receptor 124 (GPR124) (Fig. 2b). Since tight junction proteins (claudin-5 and occludin) restrict paracellular transport into the brain, barrier function was assessed by incubating beads in Lucifer yellow (LY) for 3 hours (Fig. 2c). Three conditions were tested: (1) blank beads (no dhBMECs) without LY, (2) blank beads with LY, and (3) beads with a dhBMEC monolayer with LY. The core of the beads is comprised of a permeable dextran polymer and hence beads without a dhBMEC monolayer showed high fluorescence intensity after three hours incubation with LY. In contrast, beads with a dhBMEC monolayer significantly restricted accumulation of solutes within the core ($p < 0.001$) (Fig. 2d-e). Beads with HUVEC monolayers restrict Lucifer yellow accumulation less than dhBMECs ($p = 0.028$), consistent with previous studies showing that dhBMECs display at least 10-fold lower permeability compared to HUVECs [30, 34] (Supp. Figure 2a).

3.2. Influence of chemical factors

To assess the influence of pro-angiogenic factors, we incubated BBB beads in three media conditions: (1) basal media, (2) basal media + 20 ng mL⁻¹ bFGF, and (3) basal media + 20 ng mL⁻¹ bFGF + 50 ng mL⁻¹ VEGF + 50 ng mL⁻¹ wnt7a. Across these conditions, the BBB beads were embedded within 6 mg mL⁻¹ collagen I hydrogels. In the absence growth factors, angiogenic behavior was not widely observed (Fig. 3a): after six days, only 10% of beads displayed visible sprouts (Fig. 3b). In the presence of bFGF alone, some angiogenic behavior was observed. The angiogenic fraction and maximum sprout lengths were increased compared to beads cultured in the absence of bFGF ($p = 0.026$ and $p = 0.013$, respectively), while sprout density was not statistically different ($p = 0.097$) (Fig. 3b-d). The addition of VEGF and wnt7a produced on average higher angiogenic phenotype (Fig. 3a), which was increased compared to basal conditions ($p = 0.004$, 0.012, and 0.018, respectively), but not statistically significant compared to bFGF exposure alone (Fig. 3b-d).

The average sprout length for BBB beads in VEGF and wnt7a increased linearly with time with a growth rate of approximately $20 \mu\text{m day}^{-1}$ (Fig. 3e). Confocal imaging of BBB beads cultured in VEGF and wnt7a showed extensive networks of angiogenic sprouts and formation of lumen-like structures (Fig. 3f). Sprouts on the BBB beads appear predominately comprised of tip cells, while sprouts on HUVEC beads were longer (albeit less dense) and appeared to develop tip and stalk cell appearances (Supp. Figure 2b). We also analyzed the individual contributions of VEGF and wnt7a compared to the combination of these two angiogenic factors (Supp. Figure 3). The predominant contributor to angiogenic behavior was VEGF, which displayed similar angiogenic fractions and maximum sprout lengths compared to the combination ($p = 0.990$ and 0.921 , respectively). However, sprout density most widely varied between these conditions, with wnt7a and VEGF synergistically producing the highest sprout density compared to wnt7a alone ($p = 0.030$).

3.3. Influence of extracellular matrix components

To assess the role of matrix composition, we tested four ECM conditions: (1) 6 mg mL^{-1} collagen I, (2) 6 mg mL^{-1} collagen I + 1.5 mg mL^{-1} growth factor reduced Matrigel, (3) 6 mg mL^{-1} collagen I + fibronectin, and (4) 6 mg mL^{-1} collagen I + fibrin. Matrigel is predominately comprised of laminin, along with other ECM components [35]. Across these conditions, beads were exposed to basal media + 20 ng mL^{-1} bFGF + 50 ng mL^{-1} VEGF + 50 ng mL^{-1} wnt7a. Changing ECM composition (without dramatically altering hydrogel biomechanics) had a less dramatic effect on angiogenic phenotype compared to soluble angiogenic factors: a similar sprouting morphology were observed across the conditions (Fig. 4a). The angiogenic fraction was similar across additions of ECM components and significant differences were not observed ($p > 0.05$ for all comparisons) (Fig. 4b). Matrigel supplementation led to increased sprout compared to fibronectin, suggesting that these two ECM conditions represent the most and least pro-angiogenic, respectively ($p = 0.03$) (Fig. 4c). Maximum sprout length was generally increased in response to the addition of ECM components, but was not significantly different ($p > 0.05$ for all comparisons) (Fig. 4d). For all subsequent experiments collagen I was supplemented with Matrigel to model angiogenic phenotype.

3.4. Modeling pathological angiogenesis

To model pathological brain angiogenesis, we exposed the BBB beads to high and low concentrations of hydrogen peroxide (H_2O_2) in the absence of external growth factor stimuli. H_2O_2 induces production of reactive oxygen species (ROS), whose levels are elevated during neurodegenerative disease, brain cancer, and stroke [36]. After two days exposure to $10 \mu\text{M}$ H_2O_2 , the formation of sprouts into the ECM highlights an increased angiogenic phenotype (Fig. 5a). The sprout density was significantly increased compared to vehicle treatment ($p = 0.047$) (Fig. 5b). Interestingly, the pro-angiogenic effects of $10 \mu\text{M}$ H_2O_2 were not maintained over time as by day 6 angiogenic behavior was lost, while vehicle treatment displays minor angiogenic behavior (Fig. 5c). This suggests that $10 \mu\text{M}$ H_2O_2 exerts a bimodal effect of angiogenic phenotype. Interestingly, the addition of 100-fold higher H_2O_2 (1 mM) abrogates angiogenic behavior on much shorter time scales (no sprouts are observed) (Fig. 5a-c). At this concentration cell fluorescence was gradually lost,

suggesting progressive cell death, while at all other conditions fluorescence was maintained over six days (data not shown).

3.5. Perfusable microvessel models of brain angiogenesis

Next, we tested the role of chemical cues for *in vitro* dhBMEC angiogenesis within a tissue-engineered perfusable microvessel model. These experiments mimic techniques previously demonstrated to study angiogenesis from an existing three-dimensional microvessel [29, 37, 38]. Microvessels were formed in 150 μm diameter channels within 6 mg mL^{-1} type I collagen supplemented with 1.5 mg mL^{-1} Matrigel (Fig. 6a, b). Channels were seeded with dhBMECs, which under continual $\sim 2 \text{ dyne cm}^{-2}$ perfusion, assembled into BBB microvessels, as previously reported [30]. After microvessel formation, we applied media conditions as tested in Figure 3 to observe angiogenic behavior (Fig. 6c).

Under perfusion with basal media, angiogenic behavior was not widely observed and the microvessel structure remained stable over six days (Fig. 6d). Supplementation with bFGF resulted in early sprouts within two days, which continued to grow in length and branching complexity (Fig. 6d). Supplementation with bFGF, VEGF, and wnt7a resulted in an increased density of sprouts along microvessels after two days, and chaotic sprouting behavior by six days (Fig. 6d). Both growth factor supplementation regimes were associated with loss of microvessel perfusion after 5 - 6 days due to overgrowth and constriction of microvessel lumens. Based on these results we chose to further explore bFGF supplementation over four days to promote formation of organized microvascular lumens.

3.6. Hierarchical model of the human blood-brain barrier

Lastly, we sought to engineer a hierarchical model of the human brain microvasculature by promoting sprouting between adjacent BBB microvessels. This technique has previously been demonstrated using HUVECs [29]. We patterned adjacent 150 μm diameter channels within 6 mg mL^{-1} type I collagen supplemented with 1.5 mg mL^{-1} Matrigel separated by 100 – 200 μm (Fig. 7a, b). After microvessel formation, microvessels were perfused at $\sim 2 \text{ dyne cm}^{-2}$ with basal media + 20 ng mL^{-1} bFGF (Fig. 7c). Continual perfusion over three days resulted in linking of sprouts between microvessels (Fig. 7d).

While angiogenesis and BBB formation are simultaneous during development [39], during adulthood brain angiogenesis is typically associated with BBB breakdown [40-42]. Here, we observed that both microvessels and perfusable capillaries restricted transport of 500 kDa dextran, providing evidence that lumens formed between microvessels maintain barrier function (Fig. 7e). Perfusable lumens were typically 20 – 30 μm in diameter, while smaller diameter connections between microvessels did not routinely display lumens (Fig. 7f). Further studies are required to optimize lumen formation and to fully characterize the barrier properties of this model. As BBB formation is induced via GLUT1 expression during development [10], we stained angiogenic processes to confirm robust expression of GLUT1 similar to that of parental microvessels (Fig. 7g).

4. Discussion

4.1. Factors that regulate *in vitro* brain angiogenesis

The formation of brain capillaries during development occurs through the convergence of multiple signaling pathways [2, 43, 44]. Vascular endothelial growth factor (VEGF) released by the developing neural tube initiates formation of the perineural vascular plexus (PNVP) via vasculogenesis. From the PNVP, BMECs invade the brain parenchyma via angiogenesis driven by chemical cues released by developing neurons (e.g. *wnt7a/b*) and mechanical interactions with the brain parenchyma [2, 43, 44]. The culmination of brain angiogenesis during development results in a hierarchical BBB with profound heterogeneity in structure and phenotype [42, 45, 46]. However, after development, angiogenesis is generally restricted to pathological conditions which alter BBB structure and phenotype [40-42]. Here we developed an *in vitro* model of brain angiogenesis using iPSC-derived BMECs (dhBMECs) to study brain angiogenesis. We explored multiple factors that alter angiogenic phenotype of brain microvascular endothelial cells, including growth factors, ECM composition, and oxidative stress.

Critical chemical cues implicated in developmental brain angiogenesis include vascular endothelial growth factor (VEGF) [9] and *wnt7a/b* (WNT) [10]. WNT signaling is specifically required for brain angiogenesis and is harnessed during differentiation of hiPSC-derived BMECs [14]. However, other growth factors, including basic fibroblast growth factor (bFGF), are also implicated in promoting brain angiogenesis [47, 48]. Here we found that all three growth factors are likely pro-angiogenic for dhBMECs. In previous studies of primary brain microvascular endothelial cells using a tube formation assay [6], hypoxia was found to increase VEGF expression but was insufficient to promote formation of new vessels. In contrast, we found that angiogenic factors are sufficient to promote angiogenesis of dhBMECs within a 3D microenvironment, supporting the development of more physiological angiogenesis models.

Additionally, ECM composition and stiffness are key regulators of angiogenesis [49-52]. Numerous studies have shown that increased ECM stiffness reduces angiogenesis, likely by limiting cell proliferation and migration [51, 52]. Pro-angiogenic ECM proteins include collagen I, fibronectin, and laminin [49]. In studies specific to BMECs, fibronectin and laminin were shown to promote angiogenic and maturation phenotype, respectively [53]. The extracellular space in the brain is comprised of hyaluronic acid, lecticans, proteoglycan link proteins, and tenascins [54, 55]. However, as the human brain is highly cellular by volume, non-brain-specific ECM components are commonly used to mimic the physical properties of the brain *in vitro* [3, 56, 57]. For example, 3D BBB models commonly utilize non-brain ECM components including collagen I [30, 58-62] and fibrin [23-25, 63]. We previously characterized and compared the stiffness of collagen I hydrogels to native mouse brain, and showed that 6 mg mL⁻¹ collagen is a reasonable proxy for brain stiffness [8]. Additionally, materials with stiffnesses much lower than native brain were not conducive to the formation of stable BBB microvessels [8]. Thus, we chose to only explore ECM materials with sufficient stiffness to form perfusable microvessel models, despite their absence within the brain parenchyma. We found that addition of growth factor-reduced

Matrigel (primarily composed of laminin) to a collagen I matrix increased angiogenic phenotype. Interestingly, fibronectin which plays a critical role *in vivo*, was not found to alter sprouting *in vitro*; this could result from differences in integrin expression on dhBMECs, use of suboptimal fibronectin concentrations, or differences in other microenvironmental variables. Higher concentrations of fibronectin were not tested as they required substantial alteration of bulk hydrogel mechanical properties.

Under homeostatic conditions angiogenesis is not prevalent in the adult brain, however, brain angiogenesis is associated with pathological conditions, including neurodegenerative disease, brain cancer, and stroke [42]. Production of reactive oxygen species (ROS) is associated with these conditions and may contribute to BBB disruption and pathological angiogenesis [36]. Reactive oxygen species promote angiogenesis via both VEGF-dependent and independent mechanisms [64]. Previous work utilizing primary rat BMECs found that H₂O₂ displays a concentration-dependent influence on angiogenic behavior: concentrations below 10 μ M increased tube length in a Matrigel tube formation assay, while concentrations above 10 μ M decreased tube length [5]. Here, the use of BBB beads provides spatial and temporal resolution to study the time-dependent effects of oxidative stress, which have previously been ignored. We found that H₂O₂ exerts a bimodal and concentration-dependent effect on brain angiogenesis.

4.2. Model advantages and limitations

2D models of brain angiogenesis (i.e. transwell assay or Matrigel tube forming assay) are unable to recapitulate the spatial dynamics of BMEC sprouting. Recently, 3D models of the brain microvasculature have been engineered via mimicry of vasculogenesis or angiogenesis using co-cultured primary ECs or BMECs, pericytes, and astrocytes [23-25]. Additionally, a microfluidic model of neurogenesis and angiogenesis was formed using co-cultured mesenchymal stem cells, primary BMECs, and neural stem cells, but was not tested for functional BBB properties [63]. While hiPSC-derived BMECs have been used to create microfluidic co-culture models of the BBB [19], this platform is not conducive for mimicking brain angiogenesis.

The bead assay incorporates a confluent monolayer of dhBMECs on a polymer bead which can be used in suspension or embedded in a matrix. Since there are no boundaries to the monolayer, this geometry avoids the perimeter effect associated with transwell assays. Furthermore, the bead assay uses 2000x less cells per technical replicate (i.e. one bead or transwell) and enables direct visualization of the endothelium. This model supports controlled studies of microenvironmental cues and genetic mutations on angiogenesis, without confounding factors present *in vivo*. Additionally, previous models have utilized fibrin for creating brain microvascular networks via angiogenesis and vasculogenesis-like processes [23-25]. Although neither collagen I nor fibrin is found in native brain ECM, collagen I densities used in this study are similar to the mechanical stiffness of native brain.

There are two main limitations to our model. (1) Brain angiogenesis *in vivo* occurs in the presence of complex cell-cell interactions, which are neglected in our model: BMECs interact with neurons, neural progenitor cells, pericytes, and glial progenitors during brain angiogenesis. As previously discussed, neurons and neural progenitor cells release critical

chemical stimuli including wnt ligands and VEGF, which we introduce to promote sprouting in our model. Pericytes are an important cellular component of the neurovascular unit as they physically support new capillaries and are required for the formation of the BBB during development [65, 66]. Astrocytes are not critically involved in angiogenesis, as they are not present during initial brain vascularization; however, postnatally, they release ligands that maintain BBB integrity [67]. Lastly, radial glial cells guide spatial patterning of angiogenesis as a physical scaffold for endothelial cell migration [43, 68]. Recent reports of an isogenic multicellular iPSC-based BBB transwell assay provide the foundations for building more complex angiogenesis models [69]. Additionally, we previously incorporated iPSC-derived pericytes into a 3D microvessel BBB model, showing that they do not significantly alter barrier properties [70]. Future work is required to examine how iPSC-derived pericytes and other cells of the BBB may alter angiogenesis *in vitro*. (2) The stability of angiogenic vessels is not addressed: the adult cerebrovasculature is highly stable, with limited angiogenesis [42]. For example, over 30 days changes in capillary length, diameter or branching were not observed in the adult mouse somatosensory and motor cortex [71]. Thus, models of the cerebrovasculature should aim to mimic physiological structural and phenotypic stability. We previously explored the stability of BBB microvessels, finding that microvessels reach quiescence over several days (when rates of cell division match cell apoptosis) [30]. However, the stability of microvessels formed via angiogenesis has not been addressed. As growth factor expression can display unique temporal and spatial expression patterns [9], transient administration or removal of growth factors may aid in generating stable microvessels. Future work will explore how removal of growth factors after angiogenesis occurs alters the structural and phenotypic stability of tissue-engineered cerebrovascular models. Additionally, many other stimuli influence the morphology of microvasculature *in vitro*, including flow and shear stress [50, 72], which could be harnessed to promote stability.

4.3. Engineering BBB hierarchy

To promote sprouting and anastomosis of capillaries between adjacent tissue-engineered microvessels we applied angiogenic factors which maximized growth rates. In previous work, capillary growth rates of $\sim 40 \mu\text{m day}^{-1}$ were sufficient to anastomose adjacent HUVEC microvessels [29]. Here we observed more modest growth rates for dhBMECs ($\sim 20 \mu\text{m day}^{-1}$). Previously it has been found that iPSC-derived endothelial cells exhibit reduced angiogenic potential compared to primary ECs (HUVECs), likely due to differences in MMP production [73]. Due to limitations with primary and immortalized BMEC sources we did not explore cell source-dependent angiogenic differences. Importantly, our hierarchical model allows probing of how BBB phenotype changes across the vascular tree. Recently, we demonstrated use of BBB microvessels for studying hyperosmotic BBB disruption [74], but do not know if capillaries are more susceptible to opening.

5. Conclusions

Existing *in vitro* models have generally failed to mimic brain angiogenesis or recapitulate physiological barrier function, hierarchy, and zonation of the human BBB. Here, we develop 3D *in vitro* stem cell-based models of brain angiogenesis, including a high-throughput BBB

bead assay and perfusable microvessel model. These models have diverse applications in screening the influence of chemical, mechanical, cell genotype, and stress signals on brain angiogenesis.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

RML acknowledges a National Science Foundation Graduate Research Fellowship under Grant No. DGE1746891. The authors acknowledge the assistance of Gabrielle Grifno, Matt Sklar, and Alanna Farrell with cell culture and microfabrication.

Funding

This work was supported by DTRA (HDTRA1-15-1-0046) and NIH (R01NS106008).

Abbreviations

BBB	blood-brain barrier
BMECs	brain microvascular endothelial cells
hiPSCs	human induced pluripotent stem cells
dhBMECs	hiPSC-derived BMECs
ECM	extracellular matrix
VEGF	vascular endothelial growth factor

References:

1. Zlokovic BV, Neurovascular mechanisms of Alzheimer's neurodegeneration. *Trends Neurosci*, 2005 28(4): p. 202–8. [PubMed: 15808355]
2. Zhao Z, et al., Establishment and Dysfunction of the Blood-Brain Barrier. *Cell*, 2015 163(5): p. 1064–78. [PubMed: 26590417]
3. DeStefano JG, et al., Benchmarking in vitro tissue-engineered blood-brain barrier models. *Fluids Barriers CNS*, 2018 15(1): p. 32. [PubMed: 30514389]
4. Nowak-Sliwinska P, et al., Consensus guidelines for the use and interpretation of angiogenesis assays. *Angiogenesis*, 2018 21(3): p. 425–532. [PubMed: 29766399]
5. Anasooya Shaji C, et al., The Tri-phasic Role of Hydrogen Peroxide in Blood-Brain Barrier Endothelial cells. *Sci Rep*, 2019 9(1): p. 133. [PubMed: 30644421]
6. Luo J, et al., Hypoxia induces angiogenic factors in brain microvascular endothelial cells. *Microvasc Res*, 2012 83(2): p. 138–45. [PubMed: 22100491]
7. Nakatsu MN and Hughes CC, An optimized three-dimensional in vitro model for the analysis of angiogenesis. *Methods Enzymol*, 2008 443: p. 65–82. [PubMed: 18772011]
8. Grifno GN, et al., Tissue-engineered blood-brain barrier models via directed differentiation of human induced pluripotent stem cells. *Sci Rep*, 2019 9(1): p. 13957. [PubMed: 31562392]
9. Ogunshola OO, et al., Neuronal VEGF expression correlates with angiogenesis in postnatal developing rat brain. *Brain Res Dev Brain Res*, 2000 119(1): p. 139–53. [PubMed: 10648880]
10. Daneman R, et al., Wnt/beta-catenin signaling is required for CNS, but not non-CNS, angiogenesis. *Proc Natl Acad Sci U S A*, 2009 106(2): p. 641–6. [PubMed: 19129494]

11. Thomsen MS, Routhe LJ, and Moos T, The vascular basement membrane in the healthy and pathological brain. *J Cereb Blood Flow Metab*, 2017 37(10): p. 3300–3317. [PubMed: 28753105]
12. Watase K and Zoghbi HY, Modelling brain diseases in mice: the challenges of design and analysis. *Nat Rev Genet*, 2003 4(4): p. 296–307. [PubMed: 12671660]
13. O'Brown NM, Pfau SJ, and Gu C, Bridging barriers: a comparative look at the blood-brain barrier across organisms. *Genes Dev*, 2018 32(7-8): p. 466–478. [PubMed: 29692355]
14. Lippmann ES, et al., Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. *Nat Biotechnol*, 2012 30(8): p. 783–91. [PubMed: 22729031]
15. Qian T, et al., Directed differentiation of human pluripotent stem cells to blood-brain barrier endothelial cells. *Sci Adv*, 2017 3(11): p. e1701679. [PubMed: 29134197]
16. Katt ME, et al., Human Brain Microvascular Endothelial Cells Derived from the BC1 iPS Cell Line Exhibit a Blood-Brain Barrier Phenotype. *PLoS One*, 2016 11(4): p. e0152105. [PubMed: 27070801]
17. Katt ME, et al., The role of mutations associated with familial neurodegenerative disorders on blood-brain barrier function in an iPSC model. *Fluids Barriers CNS*, 2019 16(1): p. 20. [PubMed: 31303172]
18. Lim RG, et al., Huntington's Disease iPSC-Derived Brain Microvascular Endothelial Cells Reveal WNT-Mediated Angiogenic and Blood-Brain Barrier Deficits. *Cell Rep*, 2017 19(7): p. 1365–1377. [PubMed: 28514657]
19. Vatine GD, et al., Human iPSC-Derived Blood-Brain Barrier Chips Enable Disease Modeling and Personalized Medicine Applications. *Cell Stem Cell*, 2019 24(6): p. 995–1005 e6. [PubMed: 31173718]
20. Workman MJ and Svendsen CN, Recent advances in human iPSC-derived models of the blood-brain barrier. *Fluids Barriers CNS*, 2020 17(1): p. 30. [PubMed: 32321511]
21. Sabbagh MF and Nathans J, A genome-wide view of the de-differentiation of central nervous system endothelial cells in culture. *Elife*, 2020 9.
22. Helms HC, et al., In vitro models of the blood-brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their use. *J Cereb Blood Flow Metab*, 2016 36(5): p. 862–90. [PubMed: 26868179]
23. Bang S, et al., A Low Permeability Microfluidic Blood-Brain Barrier Platform with Direct Contact between Perfusable Vascular Network and Astrocytes. *Sci Rep*, 2017 7(1): p. 8083. [PubMed: 28808270]
24. Campisi M, et al., 3D self-organized microvascular model of the human blood-brain barrier with endothelial cells, pericytes and astrocytes. *Biomaterials*, 2018 180: p. 117–129. [PubMed: 30032046]
25. Lee S, et al., 3D brain angiogenesis model to reconstitute functional human blood-brain barrier in vitro. *Biotechnol Bioeng*, 2019.
26. Gold K, Gaharwar AK, and Jain A, Emerging trends in multiscale modeling of vascular pathophysiology: Organ-on-a-chip and 3D printing. *Biomaterials*, 2018.
27. Bogorad MI, et al., Review: in vitro microvessel models. *Lab Chip*, 2015 15(22): p. 4242–55. [PubMed: 26364747]
28. Traore MA and George SC, Tissue Engineering the Vascular Tree. *Tissue Eng Part B Rev*, 2017 23(6): p. 505–514. [PubMed: 28799844]
29. Bogorad MI, et al., Tissue-engineered 3D microvessel and capillary network models for the study of vascular phenomena. *Microcirculation*, 2017 24(5).
30. Linville RM, et al., Human iPSC-derived blood-brain barrier microvessels: validation of barrier function and endothelial cell behavior. *Biomaterials*, 2019 190-191: p. 24–37. [PubMed: 30391800]
31. Kreitzer FR, et al., A robust method to derive functional neural crest cells from human pluripotent stem cells. *Am J Stem Cells*, 2013 2(2): p. 119–31. [PubMed: 23862100]
32. Katt ME, et al., Functional brain-specific microvessels from iPSC-derived human brain microvascular endothelial cells: the role of matrix composition on monolayer formation. *Fluids Barriers CNS*, 2018 15(1): p. 7. [PubMed: 29463314]

33. Huxley VH, Curry FE, and Adamson RH, Quantitative fluorescence microscopy on single capillaries: alpha-lactalbumin transport. *Am J Physiol*, 1987 252(1 Pt 2): p. H188–97. [PubMed: 3492924]
34. Faley SL, et al., iPSC-Derived Brain Endothelium Exhibits Stable, Long-Term Barrier Function in Perfused Hydrogel Scaffolds. *Stem Cell Reports*, 2019 12(3): p. 474–487. [PubMed: 30773484]
35. Hughes CS, Postovit LM, and Lajoie GA, Matrigel: a complex protein mixture required for optimal growth of cell culture. *Proteomics*, 2010 10(9): p. 1886–90. [PubMed: 20162561]
36. Pun PB, Lu J, and Mochhala S, Involvement of ROS in BBB dysfunction. *Free Radic Res*, 2009 43(4): p. 348–64. [PubMed: 19241241]
37. Nguyen DH, et al., Biomimetic model to reconstitute angiogenic sprouting morphogenesis in vitro. *Proc Natl Acad Sci U S A*, 2013 110(17): p. 6712–7. [PubMed: 23569284]
38. Pauty J, et al., A Vascular Endothelial Growth Factor-Dependent Sprouting Angiogenesis Assay Based on an In Vitro Human Blood Vessel Model for the Study of Anti-Angiogenic Drugs. *EBioMedicine*, 2018 27: p. 225–236. [PubMed: 29289530]
39. Umans RA, et al., CNS angiogenesis and barrierogenesis occur simultaneously. *Dev Biol*, 2017 425(2): p. 101–108. [PubMed: 28365243]
40. Rigau V, et al., Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy. *Brain*, 2007 130(Pt 7): p. 1942–56. [PubMed: 17533168]
41. Biron KE, et al., Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. *PLoS One*, 2011 6(8): p. e23789. [PubMed: 21909359]
42. Bogorad MI, et al., Cerebrovascular plasticity: Processes that lead to changes in the architecture of brain microvessels. *J Cereb Blood Flow Metab*, 2019 39(8): p. 1413–1432. [PubMed: 31208241]
43. Walchli T, et al., Wiring the Vascular Network with Neural Cues: A CNS Perspective. *Neuron*, 2015 87(2): p. 271–96. [PubMed: 26182414]
44. Saunders NR, Liddelow SA, and Dziegielewska KM, Barrier mechanisms in the developing brain. *Front Pharmacol*, 2012 3: p. 46. [PubMed: 22479246]
45. Nombissi ME, Galasso B, and Stins MF, Brain vascular heterogeneity: implications for disease pathogenesis and design of in vitro blood-brain barrier models. *Fluids Barriers CNS*, 2018 15(1): p. 12. [PubMed: 29688865]
46. Vanlandewijck M, et al., A molecular atlas of cell types and zonation in the brain vasculature. *Nature*, 2018 554(7693): p. 475–480. [PubMed: 29443965]
47. Chen HH, Chien CH, and Liu HM, Correlation between angiogenesis and basic fibroblast growth factor expression in experimental brain infarct. *Stroke*, 1994 25(8): p. 1651–7. [PubMed: 7518971]
48. Yukawa H, et al., Adenoviral gene transfer of basic fibroblast growth factor promotes angiogenesis in rat brain. *Gene Ther*, 2000 7(11): p. 942–9. [PubMed: 10849554]
49. Mongiat M, et al., Extracellular Matrix, a Hard Player in Angiogenesis. *Int J Mol Sci*, 2016 17(11).
50. Rao RR, et al., Matrix composition regulates three-dimensional network formation by endothelial cells and mesenchymal stem cells in collagen/fibrin materials. *Angiogenesis*, 2012 15(2): p. 253–64. [PubMed: 22382584]
51. Feng X, et al., Fibrin and collagen differentially but synergistically regulate sprout angiogenesis of human dermal microvascular endothelial cells in 3-dimensional matrix. *Int J Cell Biol*, 2013 2013: p. 231279. [PubMed: 23737792]
52. Edgar LT, et al., Extracellular matrix density regulates the rate of neovessel growth and branching in sprouting angiogenesis. *PLoS One*, 2014 9(1): p. e85178. [PubMed: 24465500]
53. Wang J and Milner R, Fibronectin promotes brain capillary endothelial cell survival and proliferation through alpha5beta1 and alphaVbeta3 integrins via MAP kinase signalling. *J Neurochem*, 2006 96(1): p. 148–59. [PubMed: 16269008]
54. Zimmermann DR and Dours-Zimmermann MT, Extracellular matrix of the central nervous system: from neglect to challenge. *Histochemistry and Cell Biology*, 2008 130(4): p. 635–653. [PubMed: 18696101]
55. Yamaguchi Y, Lecticans: organizers of the brain extracellular matrix. *Cellular and Molecular Life Sciences*, 2000 57(2): p. 276–289. [PubMed: 10766023]

56. Sykova E and Nicholson C, Diffusion in brain extracellular space. *Physiological Reviews*, 2008 88(4): p. 1277–1340. [PubMed: 18923183]
57. Placone AL, et al., Human astrocytes develop physiological morphology and remain quiescent in a novel 3D matrix. *Biomaterials*, 2015 42: p. 134–43. [PubMed: 25542801]
58. Partyka PP, et al., Mechanical stress regulates transport in a compliant 3D model of the blood-brain barrier. *Biomaterials*, 2017 115: p. 30–39. [PubMed: 27886553]
59. Cho H, et al., Three-Dimensional Blood-Brain Barrier Model for in vitro Studies of Neurovascular Pathology. *Sci Rep*, 2015 5: p. 15222. [PubMed: 26503597]
60. Adriani G, et al., A 3D neurovascular microfluidic model consisting of neurons, astrocytes and cerebral endothelial cells as a blood-brain barrier. *Lab Chip*, 2017 17(3): p. 448–459. [PubMed: 28001148]
61. Herland A, et al., Distinct Contributions of Astrocytes and Pericytes to Neuroinflammation Identified in a 3D Human Blood-Brain Barrier on a Chip. *PLoS One*, 2016 11(3): p. e0150360. [PubMed: 26930059]
62. Wevers NR, et al., A perfused human blood-brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport. *Fluids Barriers CNS*, 2018 15(1): p. 23. [PubMed: 30165870]
63. Uwamori H, et al., Integration of neurogenesis and angiogenesis models for constructing a neurovascular tissue. *Sci Rep*, 2017 7(1): p. 17349. [PubMed: 29229920]
64. Kim YW and Byzova TV, Oxidative stress in angiogenesis and vascular disease. *Blood*, 2014 123(5): p. 625–31. [PubMed: 24300855]
65. Stapor PC, et al., Pericyte dynamics during angiogenesis: new insights from new identities. *J Vasc Res*, 2014 51(3): p. 163–74. [PubMed: 24853910]
66. Daneman R, et al., Pericytes are required for blood-brain barrier integrity during embryogenesis. *Nature*, 2010 468(7323): p. 562–566. [PubMed: 20944625]
67. Alvarez JI, et al., The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. *Science*, 2011 334(6063): p. 1727–31. [PubMed: 22144466]
68. Gerhardt H, et al., Neuropilin-1 is required for endothelial tip cell guidance in the developing central nervous system. *Dev Dyn*, 2004 231(3): p. 503–9. [PubMed: 15376331]
69. Canfield SG, et al., An isogenic neurovascular unit model comprised of human induced pluripotent stem cell-derived brain microvascular endothelial cells, pericytes, astrocytes, and neurons. *Fluids Barriers CNS*, 2019 16(1): p. 25. [PubMed: 31387594]
70. Jamieson JJ, et al., Role of iPSC-derived pericytes on barrier function of iPSC-derived brain microvascular endothelial cells in 2D and 3D. *Fluids Barriers CNS*, 2019 16(1): p. 15. [PubMed: 31167667]
71. Cudmore RH, Dougherty SE, and Linden DJ, Cerebral vascular structure in the motor cortex of adult mice is stable and is not altered by voluntary exercise (vol 37, pg 3725, 2017). *Journal of Cerebral Blood Flow and Metabolism*, 2017 37(12): p. 3824–3824. [PubMed: 28139936]
72. Whisler JA, Chen MB, and Kamm RD, Control of perfusable microvascular network morphology using a multiculture microfluidic system. *Tissue Eng Part C Methods*, 2014 20(7): p. 543–52. [PubMed: 24151838]
73. Bezenah JR, Kong YP, and Putnam AJ, Evaluating the potential of endothelial cells derived from human induced pluripotent stem cells to form microvascular networks in 3D cultures. *Sci Rep*, 2018 8(1): p. 2671. [PubMed: 29422650]
74. Linville RM, et al., Modeling hyperosmotic blood-brain barrier opening within human tissue-engineered in vitro brain microvessels. *J Cereb Blood Flow Metab*, 2019: p. 271678X19867980.

Highlights:

- Bead angiogenesis model developed using iPSC-derived brain microvascular endothelial cells
- Model recapitulates blood-brain barrier protein expression and phenotype
- Model is responsive to chemical, physical, and pathological microenvironmental cues
- Sprouting phenotype optimized using VEGF, wnt ligands and pro-angiogenic ECM
- Hierarchical model generated by applying optimized stimuli within 3D microvessels

Figure 1. Three-dimensional iPSC model of brain angiogenesis.

(a) Schematic timeline of the differentiation of human induced pluripotent stem cell (hiPSC) into brain microvascular endothelial cells (dhBMECs) using sequential treatments with mTESR1, UM/F- and RA media (composition defined in Methods) over ten days on Matrigel-coated plates. (b) Phase contrast / epifluorescence overlays corresponding to steps shown in Fig. 1a. WTC iPSC line with RFP-tagged plasma membrane was used. (c) Schematic timeline of the bead angiogenesis assay showing multiplexed coating of beads with collagen IV (Cn IV) and fibronectin (Fn), seeding with dhBMECs, formation of blood-brain barrier (BBB) beads, embedding of BBB beads into extracellular matrix (ECM), and treatment with angiogenic stimuli. (d) Phase contrast / epifluorescence overlays corresponding to steps shown in Fig. 1c.

Figure 2. Characterization of BBB beads: protein expression and function.

(a) Confluent monolayers of dhBMECs on 150 μm diameter beads express localized tight junction proteins (occludin and claudin-5), the glucose transporter-1 (GLUT1) nutrient transporter, the p-glycoprotein (Pgp) efflux pump, and endothelial markers (CD31). (b) BBB beads express receptors for basic fibroblast growth factor (FGFR2), vascular endothelial growth factor (VEGFR2), and wnt7a (GPR124). Beads were incubated in 200 μM Lucifer yellow (LY) for 3 hours. Three conditions were tested: (1) blank beads without LY, (2) blank beads with LY, and (3) beads with dhBMEC monolayers with LY. (c) Quantification of LY fluorescence in a circular region of interest (ROI) within the beads using confocal microscopy (shown is corresponding phase contrast image). (d) Comparison of normalized fluorescence across conditions (N = 3). (e) Normalized fluorescence images for each condition; beads with dhBMECs significantly restrict accumulation of LY. dhBMECs were generated from the plasma membrane (PM) RFP-tagged WTC iPSC line. * $p < 0.05$. *** $p < 0.001$.

Figure 3. Influence of chemical factors on dhBMEC angiogenesis.

Three media conditions were tested: (1) basal media, (2) basal media + 20 ng mL⁻¹ bFGF, and (3) basal media + 20 ng mL⁻¹ bFGF + 50 ng mL⁻¹ VEGF + 50 ng mL⁻¹ wnt7a. Across these conditions, dhBMEC beads were embedded within 6 mg mL⁻¹ collagen I hydrogels. (a) Representative images of beads on day 2, 4 and 6 after embedding in hydrogels. Sprouts are marked with red asterisks. (b-d) Angiogenic fraction, sprout density and maximum sprout length quantified across conditions on day 6. (e) Plot of maximum sprout length over time for treatment with basal media + 20 ng mL⁻¹ bFGF + 50 ng mL⁻¹ VEGF + 50 ng mL⁻¹ wnt7a. (f) Confocal image of angiogenic processes at day 6 in basal media + 20 ng mL⁻¹ bFGF + 50 ng mL⁻¹ VEGF + 50 ng mL⁻¹ wnt7a. The image is a maximum intensity projection over a depth of 240 μm, with inset demonstrating a lumen-like structure. The

dotted circle represents the border of the bead; the dotted line represents the location of the cross-section shown in the inset. Data obtained from $N = 5$ rounds of the bead assay from unique differentiations, with greater than 5 technical replicates per differentiation. * $p < 0.05$. ** $p < 0.01$.

Figure 4. Influence of extracellular matrix components on dhBMEC angiogenesis.

Four ECM conditions were tested: (1) 6 mg mL⁻¹ collagen I, (2) 6 mg mL⁻¹ collagen I + 1.5 mg mL⁻¹ fibrin, (3) 6 mg mL⁻¹ collagen I + 1.5 mg mL⁻¹ Matrigel, (4) 6 mg mL⁻¹ collagen I + 0.5 mg mL⁻¹ fibronectin. Across these conditions, a combination of bFGF, VEGF and wnt7a were applied (media condition #3). (a) Representative images of dhBMEC beads on day 6 after embedding in hydrogels, across conditions. (b-d) Angiogenic fraction, sprout density, and maximum sprout length quantified across conditions on day 6. Data obtained from N = 5 rounds of the bead assay from unique differentiations, with greater than 5 technical replicates per differentiation. * $p < 0.05$.

Figure 5. Influence of oxidative stress on dhBMEC angiogenesis.

dhBMEC beads were exposed to vehicle (H_2O), 10 μM , and 1 mM hydrogen peroxide (H_2O_2) after embedding into collagen I + Matrigel hydrogels supplemented with basal media. (a) Phase contrast images of angiogenic behavior across conditions on day 2. Sprouts are marked with red asterisks. (b) Day 2 sprout density across conditions. (c) Time course of angiogenic fraction across conditions. Data obtained from N = 4 rounds of the bead assay from unique differentiations, with greater than 5 technical replicates per differentiation. * $p < 0.05$, ** $p < 0.01$.

Figure 6. Modeling angiogenesis from tissue-engineered brain microvessels.

(a-b) Schematic illustrations showing front and side views of model fabrication. Angiogenic factors are introduced after microvessel formation (one day after seeding BMECs) to promote sprouting. (c) Phase contrast and fluorescence image overlays of fabrication process. (d) Phase contrast and fluorescence image overlays of representative microvessels perfused with media conditions matching Figure 3. Early sprouts are marked with white asterisks.

Figure 7. Hierarchical model of the BBB via angiogenesis between existing tissue-engineered brain microvessels.

(a-b) Front and side view schematics of hierarchical model of brain angiogenesis. (c) Flow system under to control perfusion of hierarchal model. (d) Phase contrast and fluorescence image overlays of hierarchical capillary network formation. After formation in basal media, microvessels are perfused at 2 dyne cm^{-2} with 20 ng mL^{-1} bFGF to promote anastomosis of sprouts. Anastomosed capillaries are visible after 3 days. (e) Hierarchical model perfused with 500 kDa dextran for one hour. No leakage of dye was observed indicating that capillaries were intact and preserved barrier function. (f) Confocal imaging of capillary

lumen perfused with 500 kDa dextran. (g) Confocal imaging of glucose transporter-1 (GLUT1) nutrient transporter. Confocal images are shown at a specific z-plane, with the xz cross-section denoted as a dotted white line.